The incidence, risk factor, and time to develop rheumatologic diseases after isolated inflammatory eye diseases: a 12-year cohort study

Sumethkul, Kittiwan; Urailert, Indhira; Kitumnuaypong, Tassanee; Angthararak, Sungchai; Silpa-archa, Sukhum

doi:10.1007/s10067-021-06005-x

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one study had previously tested risk factors for developing rheumatological diseases 55 . However, their study was limited in that their population was unbalanced, consisting of only 75 cases.…”

Section: Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors for developing Polyautoimmunity in patients with non-infectious uveitis and their impact on visual outcomes.

de-la-Torre,

Cifuentes-González,

Rojas-Carabali

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives To identify the risk factors for PolyA development in NIU patients and determine if PolyA may be related to worse visual outcomes.Methods We investigated immune-mediated diseases in a cross-sectional study of 218 consecutive NIU patients. Univariate logistic regression and Kaplan-Meier analysis with Cox regression were performed for losing two lines of vision on the Snellen between patients with PolyA and without PolyA.Results PolyA was present in 45.9% of NIU patients. Median age at diagnosis was 44 (IQR 24–57) years, with a predominance of women (PolyA 71% vs. without PolyA 68%). Uveitis etiology shows a difference between patients with PolyA and without PolyA (autoimmune disease represents 54% PolyA vs. 0.8% without PolyA (P < 0.001)). Clinical features of PolyA uveitis included mainly bilateral, anterior, and non-granulomatous, with insidious onset and a recurrent course. The most common immunomarkers were HLA-B27 and antinuclear antibodies (ANAs), that was also significantly more frequent in PolyA patients (25% vs. 9.3% (P = 0.002)). Risk factors for developing PolyA included ages 30–64, anterior uveitis, positive ANAs, and familial autoimmunity. Kaplan-Meier analysis revealed a statistically significant increased risk of losing two lines of vision on the Snellen chart for visual acuity (HR = 2.51, 95% CI = 1.00-6.29, P = 0.049).Conclusion The development of PolyA in NIU can lead to a more rapid loss of two or more lines of vision. NIU patients aged 30–64 with anterior uveitis, familial autoimmunity, and positive ANAs require frequent follow-up to identify and manage it promptly.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

“…We also used well-de ned and previously validated PolyA 1,2 . Additionally, all the association analyses were done using previously validated factors 55 .…”

Section: Limitationsmentioning

confidence: 99%

Risk factors for developing Polyautoimmunity in patients with non-infectious uveitis and their impact on visual outcomes.

de-la-Torre,

Cifuentes-González,

Rojas-Carabali

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…An underlying systemic disease is frequently present in patients with anterior scleritis [2] . Reported comorbidities included rheumatoid arthritis (RA), ankylosing spondylitis (AS), relapsing polychondritis (RP), inflammatory bowel disease (IBD), granulomatosis with polyangiitis (GPA), and systemic lupus erythematosus (SLE) [3][4][5][6][7][8][9] . Anterior scleritis can be categorized into necrotizing, nodular, and diffuse subtypes.…”

Section: Introductionmentioning

confidence: 99%

Methotrexate for chronic non-necrotizing anterior scleritis in Chinese patients

Xiao¹,

Gao²,

Zhao³

et al. 2022

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To evaluate the effectiveness and corticosteroid-sparing capabilities of methotrexate (MTX) in the treatment of chronic non-necrotizing anterior scleritis in Chinese patients. METHODS: A retrospective chart review of all patients with active anterior scleritis between January 2015 and June 2019 was conducted. All patients received 10 to 15 mg/wk MTX orally, and corticosteroids (10 to 40 mg/d prednisolone or equivalent methylprednisolone) with slow tapering. Topical corticosteroid eye drops (1% prednisolone actate, 0.1% dexmathosone or 0.1% fluoromethalone) were applied to control comorbid anterior uveitis at presentation or during follow up. The main outcomes were inflammation control and corticosteroid-sparing success, and secondary outcomes were reduction of immunosuppression load and best-corrected visual acuity (BCVA). RESULTS: Thirty-two eyes (22 patients) were included. The proportion of patients who achieved corticosteroid-sparing success was 50.0% at 3mo and 77.3% at 12mo [8 (36.4%) patients discontinued corticosteroid]. The proportion of eyes that achieved inflammation control was 59.4% at 3mo and 78.1% at 12mo. The immunosuppression load was 5.14±0.87 at presentation and 2.76±2.34 at 12mo (P<0.01). BCVA maintained unchanged or improved in 29 (90.6%) of all affected eyes. One patient discontinued MTX treatment because of an abnormal liver function test, and no other serious adverse effects were observed. CONCLUSION: According to this pilot study, low dose MTX appear to be a well-tolerated and effective treatment for chronic non-necrotizing anterior scleritis patients in the Chinese population.

show abstract

Treatment options for necrotizing scleritis in rheumatoid arthritis patients

Kraker,

Smith

2024

Expert Review of Ophthalmology

View full text Add to dashboard Cite

The incidence, risk factor, and time to develop rheumatologic diseases after isolated inflammatory eye diseases: a 12-year cohort study

Cited by 4 publications

References 29 publications

Risk factors for developing Polyautoimmunity in patients with non-infectious uveitis and their impact on visual outcomes.

Risk factors for developing Polyautoimmunity in patients with non-infectious uveitis and their impact on visual outcomes.

Methotrexate for chronic non-necrotizing anterior scleritis in Chinese patients

Treatment options for necrotizing scleritis in rheumatoid arthritis patients

Contact Info

Product

Resources

About